API | tezosentan

tezosentan Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Tezosentan is a non-selective ETA and ETB receptor antagonist. It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events. ^Wikipedia

Chemistry

SMILES: COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO
InChIKey: TUYWTLTWNJOZNY-UHFFFAOYSA-N
Mol. Mass: 605.64
ALogP: 3.21 Partition coefficient
ChEMBL Molecule:
tezosentan

More Chemistry

Pharmacology

Mechanisms of Action:
- Endothelin-1 receptor (Homo sapiens) ^UniProt
- Endothelin receptor type B (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5-isopropyl-pyridine-2-sulfonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1h-tetrazol-5-yl--pyridin-4-yl)--pyrimidin-4-ylamide | act-050089 | ro 610612 | ro 61-0612 | ro-610612 | ro-61-0612 | tezosentan

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Heart Diseases (Phase 3)

Heart Failure (Phase 3)

Hypertension, Pulmonary (Phase 3)

Pulmonary Arterial Hypertension (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue